Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (385)	11/16/1998 10:31:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 1494

Reviewing my notes from the stockholders meeting, I can't find any reference to the AIDS-related dementia trial being used as a pivotal trial. I lack a medical background, so it could have been discussed and just did not register with me. I see from my notes that we were told that last year's trial for AIDS-related dementia enrolled just 30 patients, whereas this year's trial includes 120 patients and has experienced "faster enrollment due to the evolution of the disease." As of the date of the meeting, 90 of the 120 patients had been enrolled and they expected to complete enrollment in March. 60 patients will receive Memantine and 60 will receive placebo. The protocol calls for a 16-week blinded study, followed by a 4-week workout and a 12 week open label period (which the patient population lobbied to extend to 48 weeks). By way of background, Lisa Carr observed that 7-28% of AIDS patients suffer from dementia; 5.5-7.3% of persons with HIV infection present with dementia as the initial manifestation of the disease (the go the the clinic seeking treatment for dementia and find out for the first times that they are suffering with AIDS). JMarcus